============================================================ TITLE: Why Do Schizophrenia Trials Fail to Separate Drug from Placebo? TYPE: article VERSION: 1 VERSION_ID: 6ec02793-0502-470d-9fee-0f0ea688f3e1 GENERATED_AT: 2026-06-19T13:58:26.884Z SUMMARY: Dropout rates of 15-30% in AOM trials threaten regulatory submissions. Evidence-based strategies to improve participant retention in anti-obesity trials. AUTHOR: Signant Health DATE PUBLISHED: June 19, 2026 DATE MODIFIED: June 19, 2026 READING TIME: 13 min WORD COUNT: 2405 KEYWORDS: Key Points SOURCE URL: https://signanthealth.com/resources/why-do-schizophrenia-trials-fail-to-separate-drug-from-placebo ============================================================ KEY TAKEAWAYS: * Key Points * AUTHOR BIO * Explore Our Content Back to Resource Hub Video Why Do Schizophrenia Trials Fail to Separate Drug from Placebo? Signant Health Jun 19, 2026 Video Effect sizes in acute schizophrenia trials have been declining for decades, driven primarily by rising placebo response rather than falling treatment response. In this conversation, Dr. David Daniel, Executive Advisor, Schizophrenia at Signant Health, draws on his extensive experience in CNS drug development to identify the specific design, site selection, and data quality factors that separate successful trials from those that fail to detect signal, including peer-reviewed evidence that erratic ratings predict placebo response in both acute and negative symptom schizophrenia studies.   Key Points  Placebo response in acute schizophrenia trials has increased steadily over decades while treatment response has remained stable, making signal detection the central design challenge rather than drug efficacy itself. Inpatient trial settings control key noise sources, including medication non-adherence, substance use, and the severe daily stressors many people with schizophrenia face, contributing meaningfully to recent robust results in acute trials. Operationalizing and verifying acuity at baseline, with explicit documentation of symptoms and functional deterioration in the six to eight weeks before the trial, is a critical and frequently inadequately executed requirement. Informant interviews are worth the operational burden in schizophrenia trials given participants' poor insight, cognitive impairment, and guardedness, and should be recorded alongside the participant interview to give external reviewers the complete picture needed for accurate PANSS ratings. Peer-reviewed data co-authored by Dr. Daniel shows that erratic ratings are predictive of increased placebo response in both negative symptom and acute schizophrenia studies, and that removing sites with erratic ratings improved drug-placebo separation in studies that otherwise failed to separate. The full video contains Dr. Daniel's complete framework for trial design, site selection, informant management, scale selection for negative symptoms, and the role of blinded data analytics in protecting signal detection from start to finish.  Why It Matters Now: A Declining Effect Size Is a Design Problem, Not a Drug Problem For a person living with schizophrenia, the negative symptoms of the disease, such as social withdrawal, loss of motivation, and diminished emotional expression, represent some of its most disabling consequences. They are also the hardest to measure reliably and the most resistant to treatment. When a trial fails to separate drug from placebo, it does not necessarily mean the drug does not work. It may mean the trial was not designed or executed to detect the signal that was there. That distinction matters because it determines what happens next. A failed trial in schizophrenia consumes years of development time, exposes participants to study demands without generating usable evidence, and may result in an effective treatment never reaching the people who need it. The FDA's increasing emphasis on data quality, site oversight, and risk-based monitoring in clinical trials reflects a regulatory understanding that trial execution quality directly affects the validity of the evidence generated. For sponsors designing acute or negative symptom schizophrenia programs today, that expectation places signal detection strategy, not just drug mechanism, at the center of protocol design. What the Video Covers: Signal Detection from Protocol Design to Blinded Analytics CNS sponsors have often treated placebo response as an unavoidable feature of schizophrenia trials rather than a modifiable design variable. The peer-reviewed evidence discussed in this video challenges framing directly. Dr. Daniel describes the specific conditions under which recent acute schizophrenia trials have achieved robust drug-placebo separation: inpatient settings, verified acuity at baseline, recorded informant interviews reviewed by external raters, and principal investigator engagement at a personal level with a key sponsor contact. Each of these is operationally specific, not a general principle. On negative symptoms, Dr. Daniel distinguishes the PANSS negative factor and the NSA-16, and identifies the Brief Negative Symptom Scale and the CAINS as newer instruments that more explicitly assess anhedonia, social motivation, and the gap between what participants do and what they would like to do. That distinction matters for populations where limited social and occupational options constrain observed behavior independently of symptom severity. The blinded data analytics findings are the most directly actionable element of the discussion. Papers co-authored by Dr. Daniel with colleagues, including Dr. Alan Kott and Dr. Steve Brennan, provide published evidence that erratic rating patterns at the site level predict placebo response, and that prospective identification and exclusion of those sites improves study-level signal detection. For sponsors evaluating data quality monitoring strategy for an upcoming schizophrenia program, the full video provides the clinical and statistical reasoning behind those findings. "You really have to be attentive from start to finish in the design of your trial. The most critical ingredient of all, throughout schizophrenia trials from my perspective, is the principal investigator's involvement and relationship with a key figure in the sponsor, so that they have that emotional connection and sense of direct responsibility with a colleague that they want to do their best work for." - David Daniel, MD, Executive Advisor, Schizophrenia, Signant Health  Why do schizophrenia trials have high placebo response rates? Placebo response in acute schizophrenia trials has increased over decades while treatment response has remained stable, narrowing the drug-placebo gap. Contributing factors include insufficient acuity verification at baseline, medication non-adherence in outpatient settings, substance use, inconsistent rater quality, and inadequate informant data. Each is a modifiable design and execution variable, not an inherent feature of the disease or the drug. Do informant interviews improve data quality in schizophrenia trials? Yes. Participants with schizophrenia frequently have poor insight, cognitive impairment, and guardedness that limits self-report accuracy. Informant interviews provide context that external reviewers need to validate PANSS ratings accurately. Recording both the participant and informant interview allows external raters to conduct complete evaluations, reducing variance and the time spent reconciling discrepancies between site and central ratings. How does blinded data analytics improve signal detection in schizophrenia trials? Blinded data analytics identify site-level rating patterns predictive of increased placebo response before they compromise study outcomes. Published peer-reviewed research co-authored by David Daniel, MD, demonstrates that erratic ratings predict placebo response in both negative symptom and acute schizophrenia trials, and that prospective identification of sites with erratic patterns, followed by remediation or exclusion from enrolment, improves drug-placebo separation at the study level. AUTHOR BIO  Name: David DanielTitle and Credentials: MD, Executive Advisor, Schizophrenia at Signant Health Bio: David Daniel, MD, is Executive Advisor, Schizophrenia at Signant Health, with over 25 years of experience overseeing rater training and data quality management programs in schizophrenia and bipolar disorder clinical trials. He has supervised clinical trials across both conditions and serves as Clinical Professor of Psychiatry at George Washington University. His peer-reviewed publications on erratic ratings and placebo response in schizophrenia trials are directly referenced in this video.  This conversation is hosted by Dawie Wessels, MD, Chief Medical Officer at Signant Health. WATCH THE VIDEO Designing a signal detection strategy for an upcoming acute or negative symptom schizophrenia program? Speak to David Daniel, MD, about trial design, site selection, informant protocols, and blinded data analytics for CNS drug development. # Why Do Schizophrenia Trials Fail to Separate Drug from Placebo? Jun 19, 2026 Effect sizes in acute schizophrenia trials have been declining for decades, driven primarily by rising placebo response rather than falling treatment response. In this conversation, Dr. David Daniel, Executive Advisor, Schizophrenia at Signant Health, draws on his extensive experience in CNS drug development to identify the specific design, site selection, and data quality factors that separate successful trials from those that fail to detect signal, including peer-reviewed evidence that erratic ratings predict placebo response in both acute and negative symptom schizophrenia studies.   Key Points  Placebo response in acute schizophrenia trials has increased steadily over decades while treatment response has remained stable, making signal detection the central design challenge rather than drug efficacy itself. Inpatient trial settings control key noise sources, including medication non-adherence, substance use, and the severe daily stressors many people with schizophrenia face, contributing meaningfully to recent robust results in acute trials. Operationalizing and verifying acuity at baseline, with explicit documentation of symptoms and functional deterioration in the six to eight weeks before the trial, is a critical and frequently inadequately executed requirement. Informant interviews are worth the operational burden in schizophrenia trials given participants' poor insight, cognitive impairment, and guardedness, and should be recorded alongside the participant interview to give external reviewers the complete picture needed for accurate PANSS ratings. Peer-reviewed data co-authored by Dr. Daniel shows that erratic ratings are predictive of increased placebo response in both negative symptom and acute schizophrenia studies, and that removing sites with erratic ratings improved drug-placebo separation in studies that otherwise failed to separate. The full video contains Dr. Daniel's complete framework for trial design, site selection, informant management, scale selection for negative symptoms, and the role of blinded data analytics in protecting signal detection from start to finish.  Why It Matters Now: A Declining Effect Size Is a Design Problem, Not a Drug Problem For a person living with schizophrenia, the negative symptoms of the disease, such as social withdrawal, loss of motivation, and diminished emotional expression, represent some of its most disabling consequences. They are also the hardest to measure reliably and the most resistant to treatment. When a trial fails to separate drug from placebo, it does not necessarily mean the drug does not work. It may mean the trial was not designed or executed to detect the signal that was there. That distinction matters because it determines what happens next. A failed trial in schizophrenia consumes years of development time, exposes participants to study demands without generating usable evidence, and may result in an effective treatment never reaching the people who need it. The FDA's increasing emphasis on data quality, site oversight, and risk-based monitoring in clinical trials reflects a regulatory understanding that trial execution quality directly affects the validity of the evidence generated. For sponsors designing acute or negative symptom schizophrenia programs today, that expectation places signal detection strategy, not just drug mechanism, at the center of protocol design. What the Video Covers: Signal Detection from Protocol Design to Blinded Analytics CNS sponsors have often treated placebo response as an unavoidable feature of schizophrenia trials rather than a modifiable design variable. The peer-reviewed evidence discussed in this video challenges framing directly. Dr. Daniel describes the specific conditions under which recent acute schizophrenia trials have achieved robust drug-placebo separation: inpatient settings, verified acuity at baseline, recorded informant interviews reviewed by external raters, and principal investigator engagement at a personal level with a key sponsor contact. Each of these is operationally specific, not a general principle. On negative symptoms, Dr. Daniel distinguishes the PANSS negative factor and the NSA-16, and identifies the Brief Negative Symptom Scale and the CAINS as newer instruments that more explicitly assess anhedonia, social motivation, and the gap between what participants do and what they would like to do. That distinction matters for populations where limited social and occupational options constrain observed behavior independently of symptom severity. The blinded data analytics findings are the most directly actionable element of the discussion. Papers co-authored by Dr. Daniel with colleagues, including Dr. Alan Kott and Dr. Steve Brennan, provide published evidence that erratic rating patterns at the site level predict placebo response, and that prospective identification and exclusion of those sites improves study-level signal detection. For sponsors evaluating data quality monitoring strategy for an upcoming schizophrenia program, the full video provides the clinical and statistical reasoning behind those findings. "You really have to be attentive from start to finish in the design of your trial. The most critical ingredient of all, throughout schizophrenia trials from my perspective, is the principal investigator's involvement and relationship with a key figure in the sponsor, so that they have that emotional connection and sense of direct responsibility with a colleague that they want to do their best work for." - David Daniel, MD, Executive Advisor, Schizophrenia, Signant Health  Why do schizophrenia trials have high placebo response rates? Placebo response in acute schizophrenia trials has increased over decades while treatment response has remained stable, narrowing the drug-placebo gap. Contributing factors include insufficient acuity verification at baseline, medication non-adherence in outpatient settings, substance use, inconsistent rater quality, and inadequate informant data. Each is a modifiable design and execution variable, not an inherent feature of the disease or the drug. Do informant interviews improve data quality in schizophrenia trials? Yes. Participants with schizophrenia frequently have poor insight, cognitive impairment, and guardedness that limits self-report accuracy. Informant interviews provide context that external reviewers need to validate PANSS ratings accurately. Recording both the participant and informant interview allows external raters to conduct complete evaluations, reducing variance and the time spent reconciling discrepancies between site and central ratings. How does blinded data analytics improve signal detection in schizophrenia trials? Blinded data analytics identify site-level rating patterns predictive of increased placebo response before they compromise study outcomes. Published peer-reviewed research co-authored by David Daniel, MD, demonstrates that erratic ratings predict placebo response in both negative symptom and acute schizophrenia trials, and that prospective identification of sites with erratic patterns, followed by remediation or exclusion from enrolment, improves drug-placebo separation at the study level. AUTHOR BIO  Name: David DanielTitle and Credentials: MD, Executive Advisor, Schizophrenia at Signant Health Bio: David Daniel, MD, is Executive Advisor, Schizophrenia at Signant Health, with over 25 years of experience overseeing rater training and data quality management programs in schizophrenia and bipolar disorder clinical trials. He has supervised clinical trials across both conditions and serves as Clinical Professor of Psychiatry at George Washington University. His peer-reviewed publications on erratic ratings and placebo response in schizophrenia trials are directly referenced in this video.  This conversation is hosted by Dawie Wessels, MD, Chief Medical Officer at Signant Health. WATCH THE VIDEO Designing a signal detection strategy for an upcoming acute or negative symptom schizophrenia program? Speak to David Daniel, MD, about trial design, site selection, informant protocols, and blinded data analytics for CNS drug development. ## Key Points * Placebo response in acute schizophrenia trials has increased steadily over decades while treatment response has remained stable, making signal detection the central design challenge rather than drug efficacy itself. * Inpatient trial settings control key noise sources, including medication non-adherence, substance use, and the severe daily stressors many people with schizophrenia face, contributing meaningfully to recent robust results in acute trials. * Operationalizing and verifying acuity at baseline, with explicit documentation of symptoms and functional deterioration in the six to eight weeks before the trial, is a critical and frequently inadequately executed requirement. * Informant interviews are worth the operational burden in schizophrenia trials given participants' poor insight, cognitive impairment, and guardedness, and should be recorded alongside the participant interview to give external reviewers the complete picture needed for accurate PANSS ratings. * Peer-reviewed data co-authored by Dr. Daniel shows that erratic ratings are predictive of increased placebo response in both negative symptom and acute schizophrenia studies, and that removing sites with erratic ratings improved drug-placebo separation in studies that otherwise failed to separate. * The full video contains Dr. Daniel's complete framework for trial design, site selection, informant management, scale selection for negative symptoms, and the role of blinded data analytics in protecting signal detection from start to finish. Why It Matters Now: A Declining Effect Size Is a Design Problem, Not a Drug Problem For a person living with schizophrenia, the negative symptoms of the disease, such as social withdrawal, loss of motivation, and diminished emotional expression, represent some of its most disabling consequences. They are also the hardest to measure reliably and the most resistant to treatment. When a trial fails to separate drug from placebo, it does not necessarily mean the drug does not work. It may mean the trial was not designed or executed to detect the signal that was there. That distinction matters because it determines what happens next. A failed trial in schizophrenia consumes years of development time, exposes participants to study demands without generating usable evidence, and may result in an effective treatment never reaching the people who need it. The FDA's increasing emphasis on data quality, site oversight, and risk-based monitoring in clinical trials reflects a regulatory understanding that trial execution quality directly affects the validity of the evidence generated. For sponsors designing acute or negative symptom schizophrenia programs today, that expectation places signal detection strategy, not just drug mechanism, at the center of protocol design. What the Video Covers: Signal Detection from Protocol Design to Blinded Analytics CNS sponsors have often treated placebo response as an unavoidable feature of schizophrenia trials rather than a modifiable design variable. The peer-reviewed evidence discussed in this video challenges framing directly. Dr. Daniel describes the specific conditions under which recent acute schizophrenia trials have achieved robust drug-placebo separation: inpatient settings, verified acuity at baseline, recorded informant interviews reviewed by external raters, and principal investigator engagement at a personal level with a key sponsor contact. Each of these is operationally specific, not a general principle. On negative symptoms, Dr. Daniel distinguishes the PANSS negative factor and the NSA-16, and identifies the Brief Negative Symptom Scale and the CAINS as newer instruments that more explicitly assess anhedonia, social motivation, and the gap between what participants do and what they would like to do. That distinction matters for populations where limited social and occupational options constrain observed behavior independently of symptom severity. The blinded data analytics findings are the most directly actionable element of the discussion. Papers co-authored by Dr. Daniel with colleagues, including Dr. Alan Kott and Dr. Steve Brennan, provide published evidence that erratic rating patterns at the site level predict placebo response, and that prospective identification and exclusion of those sites improves study-level signal detection. For sponsors evaluating data quality monitoring strategy for an upcoming schizophrenia program, the full video provides the clinical and statistical reasoning behind those findings. "You really have to be attentive from start to finish in the design of your trial. The most critical ingredient of all, throughout schizophrenia trials from my perspective, is the principal investigator's involvement and relationship with a key figure in the sponsor, so that they have that emotional connection and sense of direct responsibility with a colleague that they want to do their best work for." - David Daniel, MD, Executive Advisor, Schizophrenia, Signant Health ### Why do schizophrenia trials have high placebo response rates? Placebo response in acute schizophrenia trials has increased over decades while treatment response has remained stable, narrowing the drug-placebo gap. Contributing factors include insufficient acuity verification at baseline, medication non-adherence in outpatient settings, substance use, inconsistent rater quality, and inadequate informant data. Each is a modifiable design and execution variable, not an inherent feature of the disease or the drug. ### Do informant interviews improve data quality in schizophrenia trials? Yes. Participants with schizophrenia frequently have poor insight, cognitive impairment, and guardedness that limits self-report accuracy. Informant interviews provide context that external reviewers need to validate PANSS ratings accurately. Recording both the participant and informant interview allows external raters to conduct complete evaluations, reducing variance and the time spent reconciling discrepancies between site and central ratings. ### How does blinded data analytics improve signal detection in schizophrenia trials? Blinded data analytics identify site-level rating patterns predictive of increased placebo response before they compromise study outcomes. Published peer-reviewed research co-authored by David Daniel, MD, demonstrates that erratic ratings predict placebo response in both negative symptom and acute schizophrenia trials, and that prospective identification of sites with erratic patterns, followed by remediation or exclusion from enrolment, improves drug-placebo separation at the study level. ## AUTHOR BIO Name: David DanielTitle and Credentials: MD, Executive Advisor, Schizophrenia at Signant Health Bio: David Daniel, MD, is Executive Advisor, Schizophrenia at Signant Health, with over 25 years of experience overseeing rater training and data quality management programs in schizophrenia and bipolar disorder clinical trials. He has supervised clinical trials across both conditions and serves as Clinical Professor of Psychiatry at George Washington University. His peer-reviewed publications on erratic ratings and placebo response in schizophrenia trials are directly referenced in this video.  This conversation is hosted by Dawie Wessels, MD, Chief Medical Officer at Signant Health. WATCH THE VIDEO Designing a signal detection strategy for an upcoming acute or negative symptom schizophrenia program? Speak to David Daniel, MD, about trial design, site selection, informant protocols, and blinded data analytics for CNS drug development. ## Explore Our Content Video What eCOA Data Does a Vaccine Trial Actually Need to Capture? Video Novel Endpoints in Parkinson's Trials: What Comes After UPDRS? Article Can a 10-Item PANSS Work as Well in Pediatric Trials? ### What eCOA Data Does a Vaccine Trial Actually Need to Capture? ### Novel Endpoints in Parkinson's Trials: What Comes After UPDRS? ### Can a 10-Item PANSS Work as Well in Pediatric Trials? ### Get notified on new marketing insights Here mention the benefits of subscribing ------------------------------------------------------------ FREQUENTLY ASKED QUESTIONS: Q: Why do schizophrenia trials have high placebo response rates? A: Placebo response in acute schizophrenia trials has increased over decades while treatment response has remained stable, narrowing the drug-placebo gap. Contributing factors include insufficient acuity verification at baseline, medication non-adherence in outpatient settings, substance use, inconsistent rater quality, and inadequate informant data. Each is a modifiable design and execution variable, not an inherent feature of the disease or the drug. Placebo response in acute schizophrenia trials has increased over decades while treatment response has remained stable, narrowing the drug-placebo gap. Contributing factors include insufficient acuity verification at baseline, medication non-adherence in outpatient settings, substance use, inconsistent rater quality, and inadequate informant data. Each is a modifiable design and execution variable, not an inherent feature of the disease or the drug. Do informant interviews improve data quality in schizophrenia trials? Yes. Participants with schizophrenia frequently have poor insight, cognitive impairment, and guardedness that limits self-report accuracy. Informant interviews provide context that external reviewers need to validate PANSS ratings accurately. Recording both the participant and informant interview allows external raters to conduct complete evaluations, reducing variance and the time spent reconciling discrepancies between site and central ratings. Q: Do informant interviews improve data quality in schizophrenia trials? A: Yes. Participants with schizophrenia frequently have poor insight, cognitive impairment, and guardedness that limits self-report accuracy. Informant interviews provide context that external reviewers need to validate PANSS ratings accurately. Recording both the participant and informant interview allows external raters to conduct complete evaluations, reducing variance and the time spent reconciling discrepancies between site and central ratings. Yes. Participants with schizophrenia frequently have poor insight, cognitive impairment, and guardedness that limits self-report accuracy. Informant interviews provide context that external reviewers need to validate PANSS ratings accurately. Recording both the participant and informant interview allows external raters to conduct complete evaluations, reducing variance and the time spent reconciling discrepancies between site and central ratings. How does blinded data analytics improve signal detection in schizophrenia trials? Blinded data analytics identify site-level rating patterns predictive of increased placebo response before they compromise study outcomes. Published peer-reviewed research co-authored by David Daniel, MD, demonstrates that erratic ratings predict placebo response in both negative symptom and acute schizophrenia trials, and that prospective identification of sites with erratic patterns, followed by remediation or exclusion from enrolment, improves drug-placebo separation at the study level. Q: How does blinded data analytics improve signal detection in schizophrenia trials? A: Blinded data analytics identify site-level rating patterns predictive of increased placebo response before they compromise study outcomes. Published peer-reviewed research co-authored by David Daniel, MD, demonstrates that erratic ratings predict placebo response in both negative symptom and acute schizophrenia trials, and that prospective identification of sites with erratic patterns, followed by remediation or exclusion from enrolment, improves drug-placebo separation at the study level. Blinded data analytics identify site-level rating patterns predictive of increased placebo response before they compromise study outcomes. Published peer-reviewed research co-authored by David Daniel, MD, demonstrates that erratic ratings predict placebo response in both negative symptom and acute schizophrenia trials, and that prospective identification of sites with erratic patterns, followed by remediation or exclusion from enrolment, improves drug-placebo separation at the study level. ------------------------------------------------------------ ABOUT THIS CONTENT ------------------------------------------------------------ Source: https://signanthealth.com/resources/why-do-schizophrenia-trials-fail-to-separate-drug-from-placebo Author: Signant Health Published: June 19, 2026 This content is provided for informational purposes. Please visit the original source for the most up-to-date information.